Immunovia AB (publ) IMMVF
Set alert
At close · Oct 30
- YTD
- -50.00%
- 1 year
- -80.80%
- Open
- 0.15
- Prev close
- 0.01
- Mkt cap
- 6.73M
- Vol
- 325
- Avg vol
- 62
- EPS
- -0.01
- P/E
- 0.00
More statistics
- Low
- 0.15
- High
- 0.15
News
2 months ago seekingalpha.com
Immunovia AB (publ) (IMMVF) Q2 2026 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q2 2026 Earnings Call Transcript
5 months ago seekingalpha.com
Immunovia AB (publ) (IMMVF) Q1 2026 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q1 2026 Earnings Call Transcript
8 months ago seekingalpha.com
Immunovia AB (publ) (IMMVF) Q4 2025 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q4 2025 Earnings Call Transcript
11 months ago seekingalpha.com
Immunovia AB (publ) (IMMVF) Q3 2025 Earnings Call Transcript
Immunovia AB (publ) (OTC:IMMVF) Q3 2025 Earnings Call November 26, 2025 9:00 AM EST Company Participants Jeff Borcherding - Global Chief Executive Officer & President Conference Call Participants…
1 year ago prnewswire.com
Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test
LUND, Sweden , March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of…
1 year ago prnewswire.com
Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study
LUND, Sweden , March 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its…
1 year ago prnewswire.com
Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test
LUND, Sweden , March 19, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second…
1 year ago prnewswire.com
Immunovia AB (Publ) presents Nomination Committee
LUND, Sweden , Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.…
1 year ago prnewswire.com
Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
LUND, Sweden , Dec. 18, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2…
1 year ago prnewswire.com
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of…
2 years ago prnewswire.com
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
LUND, Sweden , Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR…
2 years ago prnewswire.com
Immunovia announces updated financial calendar
LUND, Sweden , March 12, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq) (IMMNOV: Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early…
3 years ago prnewswire.com
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection
LUND, Sweden , July 12, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced plans to restructure its…
4 years ago prnewswire.com
Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase
LUND, Sweden , Aug. 23, 2022 /PRNewswire/ -- Immunovia today announced it will participate in Gilmartin Group's Emerging Growth Company Showcase on August 31, 2022. Philipp Mathieu, CEO and…